Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study


  • Aino Vesikansa MedEngine Oy, Helsinki, Finland
  • Juha Mehtälä MedEngine Oy, Helsinki, Finland
  • Marko Pesu Gilead Sciences Finland Oy, Karhumäentie 3, 01530 Vantaa, Finland
  • Jaakko Aaltonen AbbVie Oy, Pasilan Asema Aukio 1, 00520 Helsinki, Finland
  • Riikka Konttinen AbbVie Oy, Helsinki, Finland
  • Kaisa Tasanen Department of Dermatology and Medical Research Center, Oulu University Hospital; Research Group of Clinical Medicine, University of Oulu, Oulu, Finland
  • Laura Huilaja Department of Dermatology and Medical Research Center, Oulu University Hospital; PEDEGO Research Unit, University of Oulu, Oulu, Finland



Biologic, Biologic treatment, Comorbidity, Plaque psoriasis, Psoriasis vulgaris, Treatment


Therapeutic options for psoriasis vulgaris have changed during recent decades with the introduction of biologics. Few nationwide studies are available on psoriasis treatment patterns, and those from Finland predate the use of biologics. The aim of this retrospective, population-based registry study was to identify patients with psoriasis vulgaris and their treatment patterns in the secondary care setting in Finland. The study cohort included 41,456 adults with a diagnosis of psoriasis vulgaris in the public secondary healthcare setting from 2012 through 2018. Data on comorbidities, pharmacotherapy, and phototherapy were collected from nationwide healthcare and drug registries. Patients in the cohort had a wide range of comorbidities, with 14.9% having psoriatic arthritis. Treatment was based largely on topical and conventional systemic medications. Conventional medications were used by 28.9% of patients, and methotrexate was the most common option (20.9%). Biologics were used by 7.3% of patients, mostly as second- and third-line treatment. The use of conventional systemic medications, topical treatments, and phototherapy decreased after the initiation of biologics. This study of psoriasis vulgaris in Finland provides a framework for the development of future care practices. 


Download data is not yet available.


Boehncke WH, Schön MP. Psoriasis. Lancet Lond Engl 2015; 386: 983-994. DOI:

Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ 2020; 369: m1590. DOI:

Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 2020; 323: 1945-1960. DOI:

AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis - comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol 2020; 59: 566-571. DOI:

Peng C, Xu X, Chen W, Li X, Yi X, Ding Y, et al. Epidemiological variations in the global burden of psoriasis, an analysis with trends from 1990 to 2017. Front Med 2021; 8: 24. DOI:

Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol 2013; 149: 1173-1179. DOI:

Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 2010; 90: 147-151. DOI:

Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 2017; 76: 377-390. DOI:

Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35. DOI:

Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014; 134: 1542-1551. DOI:

Dalgard FJ, Gieler U, Tomas-Aragones L, Lien L, Poot F, Jemec GBE, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015; 135: 984-991. DOI:

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol 2011; 65: 137-174. DOI:

Pathirana D, Ormerod AD, Saiag P, Smith C, Spuls PI, Nast A, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70. DOI:

Psoriasis and Psoriatic Arthritis. Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim, the Finnish Dermatological Society and the Finnish Society for Rheumatology. Helsinki: The Finnish Medical Society Duodecim, 2022 (cited 2022, November 25). Available from:

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. The Lancet 2021; 397: 1301-1315. DOI:

Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2017; 12: CD011535. DOI:

Feldman SR, Kaura S, Li S, Tencer T. Treatment persistence in psoriasis patients initiated on apremilast, oral systemics, or biologic therapies. Value Health 2017; 20: A805. DOI:

Rønholt K, Iversen L. Old and new biological therapies for psoriasis. Int J Mol Sci 2017; 18: 2297. DOI:

Ragnarson Tennvall G, Hjortsberg C, Bjarnason A, Gniadecki R, Heikkilä H, Jemec GBE, et al. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol 2013; 93: 442-445. DOI:

Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R. Psoriasis causes significant economic burden to patients. Dermatol Ther 2014; 4: 115-124. DOI:

Könönen M, Torppa J, Lassus A. An epidemiological survey of psoriasis in the greater Helsinki area. Acta Derm Venereol 1986; Suppl 124: 1-10.

Sinikumpu SP, Huilaja L, Jokelainen J, Koiranen M, Auvinen J, Hägg PM, et al. High prevalence of skin diseases and need for treatment in a middle-aged population. A Northern Finland Birth Cohort 1966 study. PloS One 2014; 9: e99533. DOI:

Haverinen S, Vihervaara A, Löyttyniemi E, Peltonen S, Koulu L, Tasanen K, et al. Validation of psoriasis diagnoses recorded in Finnish biobanks. Acta Derm Venereol 2020; 100: adv00297. DOI:

Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker JNWN, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632-2640. DOI:

Duan X, Liu J, Mu Y, Liu T, Chen Y, Yu R, et al. A systematic review and meta-analysis of the association between psoriasis and hypertension with adjustment for covariates. Medicine (Baltimore) 2020; 99: e19303. DOI:

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med 2017; 376: 957-970. DOI:

Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64: ii14-17. DOI:

Fu Y, Lee CH, Chi CC. Association of psoriasis with inflammatory bowel disease: a systematic review and meta-analysis. JAMA Dermatol 2018; 154: 1417-1423. DOI:

Jousimaa J, Alenius H, Atula S, Kattainen A, Kunnamo I, Pelttari H, et al. [Phisicians' Handbook]. Duodecim; 2017.

Huilaja L, Tiri H, Jokelainen J, Timonen M, Tasanen K. Patients with hidradenitis suppurativa have a high psychiatric disease burden: a Finnish nationwide registry study. J Invest Dermatol 2018; 138: 46-51. DOI:

Markkula N, Suvisaari J, Saarni SI, Pirkola S, Peña S, Saarni S, et al. Prevalence and correlates of major depressive disorder and dysthymia in an eleven-year follow-up - results from the Finnish Health 2011 Survey. J Affect Disord 2015; 173: 73-80. DOI:

Perälä J, Suvisaari J, Saarni SI, Kuoppasalmi K, Isometsä E, Pirkola S, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007; 64: 19-28. DOI:

Ungprasert P, Wijarnpreecha K, Cheungpasitporn W. Patients with psoriasis have a higher risk of schizophrenia: a systematic review and meta-analysis of observational studies. J Postgrad Med 2019; 65: 141-145. DOI:

Svedbom A, Dalén J, Mamolo C, Cappelleri JC, Petersson IF, Ståhle M. Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis. J Eur Acad Dermatol Venereol 2015; 29: 215-223. DOI:

Murage MJ, Kern DM, Chang L, Sonawane K, Malatestinic WN, Quimbo RA, et al. Treatment patterns among patients with psoriasis using a large national payer database in the United States: a retrospective study. J Med Econ 2018; 1-9. DOI:

Hjalte F, Carlsson KS, Schmitt-Egenolf M. Sustained Psoriasis Area and Severity Index, Dermatology Life Quality Index and EuroQol-5D response of biological treatment in psoriasis: 10 years of real-world data in the Swedish National Psoriasis Register. Br J Dermatol 2018; 178: 245-252. DOI:

Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE, et al. Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis. Br J Dermatol 2018; 178: 509-519. DOI:

Egeberg A, Andersen YMF, Thyssen JP. Prevalence and characteristics of psoriasis in Denmark: findings from the Danish skin cohort. BMJ Open 2019; 9: e028116. DOI:

Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD, et al. Identification of factors that may influence the selection of first-line biological therapy for people with psoriasis: a prospective, multicentre cohort study. Br J Dermatol 2017; 177: 828-836. DOI:

van den Reek JMPA, Seyger MMB, van Lümig PPM, Driessen RJB, Schalkwijk CJM, Berends MAM, et al. The journey of adult psoriasis patients towards biologics: past and present - results from the BioCAPTURE registry. J Eur Acad Dermatol Venereol 2018; 32: 615-623. DOI:

Additional Files



How to Cite

Vesikansa, A., Mehtälä, J., Pesu, M., Aaltonen, J., Konttinen, R., Tasanen, K., & Huilaja, L. (2023). Comorbidities and Medication Use in Finnish Patients with Psoriasis: A Population-Based Registry Study. Acta Dermato-Venereologica, 103, adv00886.

Most read articles by the same author(s)

1 2 3 > >>